Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Optimized Background Regimen (OBR) Clear all
Completed Phase 1Phase 2 Interventional Results available

Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

NCT01504841
View directory record Official record
Conditions
HIV Infections
Interventions
Etravirine (ETR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Miami, Florida • Chicago, Illinois • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 3 Interventional

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

NCT00254046
View directory record Official record
Conditions
HIV
Interventions
TMC125, Placebo
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
32
States / cities
Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 17, 2026, 9:16 AM EDT
Recruiting Phase 2 Interventional

Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children

NCT06749054
View directory record Official record
Conditions
HIV-1-infection
Interventions
Oral Lenacapavir, Subcutaneous Lenacapavir, Optimized Background Regimen (OBR)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir

NCT01568892
View directory record Official record
Conditions
HIV Infections
Interventions
Dolutegravir 50 mg twice daily, Dolutegravir placebo twice daily
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
25
States / cities
Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

NCT00665847
View directory record Official record
Conditions
HIV-1
Interventions
Etravirine (TMC125), Optimized background regimen (OBR)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
6 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Mobile, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 17, 2026, 9:16 AM EDT
Terminated Phase 3 Interventional Results available

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

NCT00440271
View directory record Official record
Conditions
HIV Infections
Interventions
tipranavir, ritonavir, Optimized Background Regimen (OBR)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
16
States / cities
Washington D.C., District of Columbia • Clearwater, Florida • Fort Lauderdale, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 17, 2026, 9:16 AM EDT
Terminated Phase 2 Interventional

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

NCT01026727
View directory record Official record
Conditions
HIV Infections
Interventions
MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Beverly Hills, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2010 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

NCT00515827
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir (MK-0518), Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 17, 2026, 9:16 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

NCT05327803
View directory record Official record
Conditions
MAC Lung Disease, Treatment Refractory MAC Lung Disease
Interventions
Epetraborole, Placebo
Drug
Lead sponsor
AN2 Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
49
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

NCT00685360
View directory record Official record
Conditions
Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis
Interventions
Delamanid, Optimized Background Regimen (OBR), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 17, 2026, 9:16 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

NCT04150068
View directory record Official record
Conditions
HIV-1-infection
Interventions
Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir, Failing ARV Regimen, Optimized Background Regimen (OBR)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
35
States / cities
Los Angeles, California • Palm Springs, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

NCT02707861
View directory record Official record
Conditions
HIV
Interventions
ibalizumab, Optimized Background Regimen
Drug
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Long Beach, California • Los Angeles, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

NCT02475629
View directory record Official record
Conditions
HIV
Interventions
ibalizumab, Optimized Background Regimen (OBR)
Biological · Drug
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
27
States / cities
Long Beach, California • Los Angeles, California • Palm Springs, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 17, 2026, 9:16 AM EDT